A highly efficient way to recycle inactive stereoisomers of Bedaquiline into two previous intermediates via base-catalyzed Csp3-Csp3 bond cleavage
English
A highly efficient way to recycle inactive stereoisomers of Bedaquiline into two previous intermediates via base-catalyzed Csp3-Csp3 bond cleavage
-
Key words:
- Bedaquiline
- / Inactive stereoisomers
- / Recycle
- / Csp3-Csp3 cleavage
-
-
-
[1] E. Cox, K. Laessig, FDA approval of bedaquiline-the benefit-risk balance for drugresistant tuberculosis, N. Engl. J. Med. 371 (2014) 689-691.[1] E. Cox, K. Laessig, FDA approval of bedaquiline-the benefit-risk balance for drugresistant tuberculosis, N. Engl. J. Med. 371 (2014) 689-691.
-
[2] R.V. Patel, S.D. Riyaz, S.W. Park, Bedaquiline: a new hope to treat multi-drug resistant tuberculosis, Curr. Top Med. Chem. 14 (2014) 1866-1874.[2] R.V. Patel, S.D. Riyaz, S.W. Park, Bedaquiline: a new hope to treat multi-drug resistant tuberculosis, Curr. Top Med. Chem. 14 (2014) 1866-1874.
-
[3] C.U. Köser, B. Javid, K. Liddell, et al., Drug-resistance mechanisms and tuberculosis drugs, Lancet 385 (2015) 305-307.[3] C.U. Köser, B. Javid, K. Liddell, et al., Drug-resistance mechanisms and tuberculosis drugs, Lancet 385 (2015) 305-307.
-
[4] (a) G. Jerome Emile Georges, V. Gestel, J.F. Elisabetha, et al., Quinoline derivatives and their use as mycobacterial inhibitors, PCT Int. Appl. (2004), WO2004011436A1; (b) P. Frank Ralf, H. Stefan, B. Thomas, Process for preparing (aS, bR)-6-bromo-a-[2-(dimethylamino)ethyl]-2-methoxy-a-1-naphthaleny-b-phenyl-3-quiolineethanol, PCT Int. Appl. (2006), WO2006125769.[4] (a) G. Jerome Emile Georges, V. Gestel, J.F. Elisabetha, et al., Quinoline derivatives and their use as mycobacterial inhibitors, PCT Int. Appl. (2004), WO2004011436A1; (b) P. Frank Ralf, H. Stefan, B. Thomas, Process for preparing (aS, bR)-6-bromo-a-[2-(dimethylamino)ethyl]-2-methoxy-a-1-naphthaleny-b-phenyl-3-quiolineethanol, PCT Int. Appl. (2006), WO2006125769.
-
[5] N. Lounis, J. Guillemont, N. Veziris, et al., R207910 (TMC207): a new antibiotic for the treatment of tuberculosis, Méd. Mal. Infect. 40 (2010) 383-390.[5] N. Lounis, J. Guillemont, N. Veziris, et al., R207910 (TMC207): a new antibiotic for the treatment of tuberculosis, Méd. Mal. Infect. 40 (2010) 383-390.
-
[6] Y. Saga, R. Motoki, S. Makino, et al., Catalytic asymmetric synthesis of R207910, J. Am. Chem. Soc. 132 (2010) 7905-7907.[6] Y. Saga, R. Motoki, S. Makino, et al., Catalytic asymmetric synthesis of R207910, J. Am. Chem. Soc. 132 (2010) 7905-7907.
-
[7] S. Chandrasekhar, G.S. Kiran Babu, D.K. Mohapatra, Practical syntheses of (2S)-R207910 and (2R)-R207910, Eur. J. Org. Chem. 11 (2011) 2057-2061.[7] S. Chandrasekhar, G.S. Kiran Babu, D.K. Mohapatra, Practical syntheses of (2S)-R207910 and (2R)-R207910, Eur. J. Org. Chem. 11 (2011) 2057-2061.
-
[8] P.J. Hamrick Jr., C.R. Hauser, The reversible addition of sodiodiphenylmethide to benzophenone in liquid ammonia, base-catalyzed cleavage of 1,1,2,2-tetraphenylethanol, J. Am. Chem. Soc. 81 (1959) 3144-3147.[8] P.J. Hamrick Jr., C.R. Hauser, The reversible addition of sodiodiphenylmethide to benzophenone in liquid ammonia, base-catalyzed cleavage of 1,1,2,2-tetraphenylethanol, J. Am. Chem. Soc. 81 (1959) 3144-3147.
-
-
扫一扫看文章
计量
- PDF下载量: 0
- 文章访问数: 1492
- HTML全文浏览量: 110

下载: